Clinical Trial: A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).

U.S., Aug. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07784101) titled 'A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).' on Aug. 17.

Brief Summary: This study aims to compare the efficacy and safety of ICP-248 in combination with orelabrutinib versus pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma (r/r MCL).

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Intervention: DRUG: ICP-248

Administered orally

DRUG: Pirtobrutinib

Administered orally

DRUG: Orelabrutinib

Admin...